These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 26936993)

  • 1. FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway.
    Ji W; Yu Y; Li Z; Wang G; Li F; Xia W; Lu S
    Oncotarget; 2016 Mar; 7(12):15118-34. PubMed ID: 26936993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
    Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
    Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells.
    Yuan H; Li ZM; Shao J; Ji WX; Xia W; Lu S
    J Exp Clin Cancer Res; 2017 May; 36(1):72. PubMed ID: 28558758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HEDGEHOG/GLI Modulates the PRR11-SKA2 Bidirectional Transcription Unit in Lung Squamous Cell Carcinomas.
    Sun Y; Xu D; Zhang C; Wang Y; Zhang L; Qiao D; Bu Y; Zhang Y
    Genes (Basel); 2021 Jan; 12(1):. PubMed ID: 33477943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.
    Adachi Y; Watanabe K; Kita K; Kitai H; Kotani H; Sato Y; Inase N; Yano S; Ebi H
    Carcinogenesis; 2017 Oct; 38(11):1063-1072. PubMed ID: 28968756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hedgehog signaling pathway molecules and ALDH1A1 expression in early-stage non-small cell lung cancer.
    Raz G; Allen KE; Kingsley C; Cherni I; Arora S; Watanabe A; Lorenzo CD; Edwards V DK; Sridhar S; Hostetter G; Weiss GJ
    Lung Cancer; 2012 May; 76(2):191-6. PubMed ID: 22115706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer.
    Wang K; Ji W; Yu Y; Li Z; Niu X; Xia W; Lu S
    Oncogene; 2018 Sep; 37(39):5340-5354. PubMed ID: 29858603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.
    Malchers F; Dietlein F; Schöttle J; Lu X; Nogova L; Albus K; Fernandez-Cuesta L; Heuckmann JM; Gautschi O; Diebold J; Plenker D; Gardizi M; Scheffler M; Bos M; Seidel D; Leenders F; Richters A; Peifer M; Florin A; Mainkar PS; Karre N; Chandrasekhar S; George J; Silling S; Rauh D; Zander T; Ullrich RT; Reinhardt HC; Ringeisen F; Büttner R; Heukamp LC; Wolf J; Thomas RK
    Cancer Discov; 2014 Feb; 4(2):246-57. PubMed ID: 24302556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.
    Singleton KR; Hinz TK; Kleczko EK; Marek LA; Kwak J; Harp T; Kim J; Tan AC; Heasley LE
    Cancer Res; 2015 Oct; 75(20):4398-406. PubMed ID: 26359452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.
    Weiss J; Sos ML; Seidel D; Peifer M; Zander T; Heuckmann JM; Ullrich RT; Menon R; Maier S; Soltermann A; Moch H; Wagener P; Fischer F; Heynck S; Koker M; Schöttle J; Leenders F; Gabler F; Dabow I; Querings S; Heukamp LC; Balke-Want H; Ansén S; Rauh D; Baessmann I; Altmüller J; Wainer Z; Conron M; Wright G; Russell P; Solomon B; Brambilla E; Brambilla C; Lorimier P; Sollberg S; Brustugun OT; Engel-Riedel W; Ludwig C; Petersen I; Sänger J; Clement J; Groen H; Timens W; Sietsma H; Thunnissen E; Smit E; Heideman D; Cappuzzo F; Ligorio C; Damiani S; Hallek M; Beroukhim R; Pao W; Klebl B; Baumann M; Buettner R; Ernestus K; Stoelben E; Wolf J; Nürnberg P; Perner S; Thomas RK
    Sci Transl Med; 2010 Dec; 2(62):62ra93. PubMed ID: 21160078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer.
    Lu T; Li Z; Yang Y; Ji W; Yu Y; Niu X; Zeng Q; Xia W; Lu S
    Cancer Lett; 2018 Jun; 423():36-46. PubMed ID: 29452146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hedgehog-GLI signaling inhibition suppresses tumor growth in squamous lung cancer.
    Huang L; Walter V; Hayes DN; Onaitis M
    Clin Cancer Res; 2014 Mar; 20(6):1566-75. PubMed ID: 24423612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLI2 induces PDGFRB expression and modulates cancer stem cell properties of gastric cancer.
    Wang JX; Zhou JF; Huang FK; Zhang L; He QL; Qian HY; Lai HL
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(17):3857-3865. PubMed ID: 28975979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandin E1 Inhibits
    Wu F; Zhang C; Zhao C; Wu H; Teng Z; Jiang T; Wang Y
    Cancer Res; 2020 Jul; 80(13):2818-2832. PubMed ID: 32371475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
    Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
    Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrantly activated Gli2-KIF20A axis is crucial for growth of hepatocellular carcinoma and predicts poor prognosis.
    Shi C; Huang D; Lu N; Chen D; Zhang M; Yan Y; Deng L; Lu Q; Lu H; Luo S
    Oncotarget; 2016 May; 7(18):26206-19. PubMed ID: 27036048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
    Aggarwal C; Redman MW; Lara PN; Borghaei H; Hoffman P; Bradley JD; Newman AJ; Feldman MJ; Minichiello K; Miao J; Mack PC; Papadimitrakopoulou VA; Herbst RS; Kelly K; Gandara DR
    J Thorac Oncol; 2019 Oct; 14(10):1847-1852. PubMed ID: 31195180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hedgehog and TGFβ signaling converge on Gli2 to control bony invasion and bone destruction in oral squamous cell carcinoma.
    Cannonier SA; Gonzales CB; Ely K; Guelcher SA; Sterling JA
    Oncotarget; 2016 Nov; 7(46):76062-76075. PubMed ID: 27738315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reciprocal FGF19-GLI2 signaling induces epithelial-to-mesenchymal transition to promote lung squamous cell carcinoma metastasis.
    Zhang Y; Wu T; Wang Y; Chen Z; Chen J; Lu S; Xia W
    Cell Oncol (Dordr); 2023 Apr; 46(2):437-450. PubMed ID: 36598638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.